Advertisement

Association of Cornell product with metabolic syndrome in middle-aged people in China

  • Feng Xuefang
  • Yu Jianfeng
  • Sun Shuiya
  • Chen Xiaoying
  • Zhou JiaqiangEmail author
Original Article
  • 12 Downloads

Abstract

Background

Metabolic syndrome (MS) has attracted much attention worldwide for its harmful effects. Although the Cornell product (CP) and Sokolow-Lyon (SL) voltage are independent and strong risk factors of cardiovascular disease, their associations with MS and the relative strength of these associations are unknown. Therefore, we studied these aspects in a community of middle-aged people.

Methods

A total of 1112 community residents aged 40–65 years, among which 169 had IDF (2005)–defined MS (MS group) and 943 did not have MS (NMS group), underwent electrocardiography (ECG) at baseline. A questionnaire survey, physical measurements, laboratory biochemical assessments, urine test, ECG, body fat analysis, and abdominal MRI examination were performed subsequently. Fifty-eight participants had developed MS (new-onset MS group) at the follow-up, while 472 residents had not developed MS over the next year (MS-free group). We compared the CP and SL voltage between these two groups.

Results

In the overall analysis, CP values were higher in the MS group than in the NMS group (p < 0.05), but SL voltage values were not significantly different (p > 0.05). In the gender-stratified multivariate analysis, CP was significantly different in the male and female populations (p < 0.05), but SL voltage was only different in the male population (p = 0.042). After removing hypertension from MS and NMS groups, there was still significant difference in CP value (< 0.05). Thus, CP showed a more pronounced influence. The new-onset MS group showed significantly higher CP values and the changes in CP values than did the MS-free group at baseline and follow-up (p < 0.05), but the changes in SL values were not significant (p > 0.05).

Conclusions

CP values differed significantly between the MS and NMS groups. The new-onset MS group showed higher baseline CP values. Thus, CP is more advantageous than SL voltage in presaging the incidence of MS-related cardiovascular risk.

Keywords

Cornell product Sokolow-Lyon voltage Electrocardiogram Metabolic syndrome 

Notes

Funding information

This work was supported by the National Key Technology R&D Program of China (No. 2009BAI80B02).

Compliance with ethical standards

The study was approved by the ethics committee of Sir Run Run Shaw Hospital.

References

  1. 1.
    Arnlov J, Lind L, Zethelius B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J. 2001;142(4):720–4.CrossRefGoogle Scholar
  2. 2.
    Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol. 2004;93(1):40–4.CrossRefGoogle Scholar
  3. 3.
    Ingelsson E, Arnlov J, Lind L, Sundstrom J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart. 2006;92(10):1409–13.CrossRefGoogle Scholar
  4. 4.
    Otaki Y, Takahashi H, Watanabe T, et al. Electrocardiographic left ventricular hypertrophy Cornell product is a feasible predictor of cardiac prognosis in patients with chronic heart failure. Clin Res Cardiol. 2014;103(4). Germany):275–84.CrossRefGoogle Scholar
  5. 5.
    Ishikawa J, Ishikawa S, Kario K. Levels of Cornell voltage and Cornell product for predicting cardiovascular and stroke mortality and morbidity in the general Japanese population. Circ J. 2014;78(2):465–75.CrossRefGoogle Scholar
  6. 6.
    Santhanakrishnan R, Wang N, Larson MG, Magnani JW, Vasan RS, Wang TJ, et al. Racial differences in electrocardiographic characteristics and prognostic significance in Whites versus Asians. J Am Heart Assoc. 2016;5(3):e002956.CrossRefGoogle Scholar
  7. 7.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.CrossRefGoogle Scholar
  8. 8.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.CrossRefGoogle Scholar
  9. 9.
    Rigato M, Boscari F, Marcuzzo G, et al. Development of metabolic syndrome and electrocardiographic features of left ventricular hypertrophy in middle-aged working subjects. J Endocrinol Investig. 2013;36(11):1027–31.Google Scholar
  10. 10.
    Holmang A, Yoshida N, Jennische E, Waldenstrom A, Bjorntorp P. The effects of hyperinsulinaemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur J Clin Investig. 1996;26(11):973–8.CrossRefGoogle Scholar
  11. 11.
    Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003;26(8):2433–41.CrossRefGoogle Scholar
  12. 12.
    Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlof B. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension. 2000;35:1 Pt 1): 13–8.CrossRefGoogle Scholar
  13. 13.
    Sosner P, Cabasson S, Hulin-Delmotte C, Saulnier PJ, Gand E, Torremocha F, et al. Effect of Cornell product and other ECG left ventricular hypertrophy criteria on various cardiovascular endpoints in type 2 diabetic patients. Int J Cardiol. 2014;175(1):193–5.CrossRefGoogle Scholar
  14. 14.
    Park JK, Shin JH, Kim SH, Lim YH, Kim KS, Kim SG, et al. A comparison of Cornell and Sokolow-Lyon electrocardiographic criteria for left ventricular hypertrophy in Korean patients. Korean Circ J. 2012;42(9):606–13.CrossRefGoogle Scholar
  15. 15.
    Ishikawa J, Yamanaka Y, Toba A, Watanabe S, Harada K. Gender-adjustment and cutoff values of Cornell product in hypertensive Japanese patients. Int Heart J. 2017;58(6):933–8.CrossRefGoogle Scholar
  16. 16.
    Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Blood Press. 2001;10(2):74–82.CrossRefGoogle Scholar
  17. 17.
    Sundstrom J, Lind L, Arnlov J, Zethelius B, Andren B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation. 2001;103(19):2346–51.CrossRefGoogle Scholar
  18. 18.
    Rodriguez-Padial L, Bacharova L. Electrical remodeling in left ventricular hypertrophy-is there a unifying hypothesis for the variety of electrocardiographic criteria for the diagnosis of left ventricular hypertrophy. J Electrocardiol. 2012;45(5):494–7.CrossRefGoogle Scholar
  19. 19.
    Pewsner D, Juni P, Egger M, Battaglia M, Sundstrom J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335(7622):711.CrossRefGoogle Scholar
  20. 20.
    Okin PM, Devereux RB, Harris KE, et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension. 2007;50(5):984–90.CrossRefGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2019

Authors and Affiliations

  • Feng Xuefang
    • 1
    • 2
  • Yu Jianfeng
    • 3
  • Sun Shuiya
    • 1
  • Chen Xiaoying
    • 2
  • Zhou Jiaqiang
    • 1
    Email author
  1. 1.Department of Endocrinology, Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhouChina
  2. 2.Department of GeneralCi Xi People’s HospitalCixiChina
  3. 3.Ci Xi Center for Disease Control and PreventionCixiChina

Personalised recommendations